# The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome

> **NCT04422327** · PHASE1,PHASE2 · COMPLETED · sponsor: **PrecisionBiotics Group Ltd.** · enrollment: 40 (actual)

## Conditions studied

- IBS - Irritable Bowel Syndrome
- Depression, Anxiety

## Interventions

- **DIETARY_SUPPLEMENT:** Probiotic capsule

## Key facts

- **NCT ID:** NCT04422327
- **Lead sponsor:** PrecisionBiotics Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2018-02-12
- **Final completion:** 2018-02-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04422327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04422327, "The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04422327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*